Skip to main content

Human OCIL/CLEC2d Antibody

R&D Systems, part of Bio-Techne | Catalog # AF3480

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
AF3480
AF3480-SP

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

CyTOF-ready, Flow Cytometry, Western Blot

Cited:

Immunohistochemistry

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

E. coli-derived recombinant human OCIL/CLEC2d
Ser57-Val191
Accession # Q9UHP7

Specificity

Detects human OCIL/CLEC2d in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse (rm) OCIL is observed and less than 1% cross-reactivity with recombinant human (rh) CLEC2B, and rhCLEC2A is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for Human OCIL/CLEC2d Antibody

Detection of OCIL/CLEC2d antibody in Raji Human Cell Line antibody by Flow Cytometry.

Detection of OCIL/CLEC2d in Raji Human Cell Line by Flow Cytometry.

Raji human Burkitt's lymphoma cell line was stained with Goat Anti-Human OCIL/CLEC2d Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3480, filled histo­gram) or control antibody (Catalog # AB-108-C, open histo­gram), followed by Phycoerythrin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0107).

Applications for Human OCIL/CLEC2d Antibody

Application
Recommended Usage

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

2.5 µg/106 cells
Sample: Raji human Burkitt's lymphoma cell line

Western Blot

0.1 µg/mL
Sample: Recombinant Human OCIL/CLEC2d

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: OCIL/CLEC2d

Human OCIL/CLEC2d, also known as Lectin-Like Transcript-1 (LLT-1), is a type II transmembrane protein belonging to the natural killer (NK) cell receptor group of the C-type lectin superfamily. It is found on hematopoietic cells, osteoblasts, and chondrocytes. By alternative splicing, at least three isoforms exist. Isoform 1 is synthesized as a 191 amino acid (aa) precursor with a C-terminal 132 aa extracellular domain (ECD) that contains the C-type lectin domain. The aa sequence of human OCIL isoform 1 ECD is 49% and 50% identical to the mouse and rat OCIL ECD, respectively. Human OCIL preferentially binds high molecular weight sulfated glycosaminoglycans and is a ligand for the single human NKR-P1A receptor (CD161). Human OCIL blocks osteoclast differentiation. Engagement of OCIL with CD161 on NK cells also inhibits NK cell-mediated cytotoxicity and IFN-gamma secretion.

Long Name

Osteoclast Inhibitory Lectin

Alternate Names

CLEC2D, LLT1

Entrez Gene IDs

29121 (Human); 93694 (Mouse)

Gene Symbol

CLEC2D

UniProt

Additional OCIL/CLEC2d Products

Product Documents for Human OCIL/CLEC2d Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human OCIL/CLEC2d Antibody

For research use only

Loading...
Loading...
Loading...
Loading...
Loading...